Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
13-Week Study to Evaluate the Safety and Efficacy of VK2735 Dosed Weekly Trial Size Increased from 125 to 176 Patients Due to Elevated Demand SAN DIEGO, Oct. 23, 2023 /PRNewswire/ -- Viking...
Ligand Pharmaceuticals Incorporated Therapeutics Inc Obesity Society Drug Administration Prnewswire Viking Therapeutics Inc Week Study
Source: marketscreener.com